Job Description
About Immunai:
Immunai is an engineering-first platform company aiming to improve therapeutic decision-making throughout the drug discovery and development process. We are mapping the immune system at unprecedented scale and granularity and applying machine learning to this massive clinico-immune database, in order to generate novel insights into disease pathology for our partners - pharma companies and research institutes. We provide a comprehensive, end-to-end solution - from data generation and curation to therapeutics development, that continuously supports and validates the capabilities of our platform.
As drug development is becoming increasingly inefficient, our ultimate goal is to help bring breakthrough medicines to patients as quickly and successfully as possible.
Immunai is an equal opportunity employer. We celebrate diversity and are committed to creating an inclusive environment for all employees.
About the role:
As a (Senior) Director of Preclinical Programs, you will lead a team of scientists to design and engineer immune-modulating biologics, and advance candidate molecules from hit-to-lead by integrating traditional preclinical pharmacology approaches with Immunai’s platform-enabled workflows for preclinical asset evaluation. You will identify, prioritize and optimize promising lead molecules for potential partnering or investment for internal development.
Location: New York, NY (hybrid model)
What will you do?
Required qualifications:
Desired personal traits:
Compensation: This position offers a salary typically between $200,000 and $275,000. There is an opportunity to consider higher compensation above this range based on business need, candidate experience, and or skills.
*Please note that when you apply for a position at Immunai, your application will be processed via our recruitment platform Comeet. You can read more about how we process personal data here: https://www.immunai.com/privacy-policy/
Immunai is a biotech company that combines single-cell genomics with ML algorithms to enable high-resolution profiling of the immune system. Immunai's mission is to map the entire immune system and its functions using single-cell genomics and machine learning. Immunai leverages single-cell technologies to profile cells from a blood sample, and uses machine-learning algorithms (powered by its proprietary database) to map the hundreds of cell types and their states to create an immune profile. They work on biomarker discovery and insights that identify how a cell responds to its changing environment. The company is located in New York City, San Francisco, and Tel Aviv, Israel.
